EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

BASDAI and ASDAS disease states in relationship to ASAS40 response: post hoc analysis of ixekizumab in radiographic axial spondyloarthritis

Martin Rudwaleit iD, Victoria Navarro-Compán iD, Hagen Russ, Tommaso Panni, Erica Filippi, Mani Haschemi Nassab, Soyi Liu-Leage, Vincent Goëb, Francesco Ciccia iD, Jean Dudler iD

Rheumatology Advances in Practice · 14.03.2025 · 9 (2)

DOI: 10.1093/rap/rkaf012 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Rheumatology Advances in Practice, online erschienen am 29.01.2025. Verfasst von Martin Rudwaleit und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology, Klinikum Bielefeld, Medical School and University Center OWL, Bielefeld University, Bielefeld, Germany. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Eli Lilly and Company.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

To explore the relationship between Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and Axial Spondyloarthritis Disease Activity Score (ASDAS) used in clinical practice and the Assessment of SpondyloArthritis international Society 40% (ASAS40) response, the primary endpoint in clinical trials in axial spondyloarthritis (axSpA).

Methods

Data from COAST-V, a phase 3 trial of ixekizumab vs placebo in biologic-naïve radiographic axSpA (r-axSpA) patients, were analysed. Patients treated with ixekizumab every 4 weeks were categorized using the ASAS40 response at week 16 and 52. The association between BASDAI and ASDAS disease states, respectively, and ASAS40 response achieved/not achieved was investigated. Additionally, back pain, fatigue, Bath Ankylosing Spondylitis Functional Index, ASAS Health Index and 36-item Short Form Health Survey Physical Component Summary scores corresponding to these states were assessed. Results were reported descriptively.

Results

After 16 weeks, 48.1% (39/81) of patients achieved an ASAS40 response. Among them, 71.8% (n = 28) and 43.6% (n = 17) achieved BASDAI <3 and BASDAI <2, respectively; 76.9% (n = 30) and 33.3% (n = 13) attained ASDAS <2.1 and ASDAS <1.3, respectively. Among ASAS40 responders at week 52 [53.1% (43/81)], 83.8% (n = 36) and 51.2% (n = 22) of patients achieved BASDAI <3 and BASDAI <2, respectively; 93.1% (n = 40) and 41.9% (n = 18) attained ASDAS <2.1 and ASDAS <1.3. Lower BASDAI and ASDAS disease states corresponded well with less back pain, fatigue and functioning impairment and better health-related quality of life.

Conclusions

More than 70% of biologic-naïve r-axSpA patients who achieved an ASAS40 response, also attained low disease activity or inactive disease as measured by the BASDAI or ASDAS. Findings may help clinicians translate results from clinical trials into daily practice.

Schlagwörter

Stichwörter der Autor:innen

axial spondyloarthritisdisease activityixekizumaboutcometreatment response

Autor:innen und Institutionen

  • Department of Rheumatology, Klinikum Bielefeld, Medical School and University Center OWL, Bielefeld University, Bielefeld, Germany.
  • Department of Rheumatology, University Hospital La Paz, IdiPAZ, Madrid, Spain.
  • Eli Lilly and Company, Indianapolis, IN, USA.
  • Department of Rheumatology, Centre Hospitalier Universitaire Amiens-Picardie, UPJV, Amiens, France.
  • Department of Rheumatology, University of Palermo, Sicily, Italy.
  • Department of Rheumatology, Hôpital Fribourgeois, Fribourg, Switzerland.

ORCID-Profile: Martin Rudwaleit, Victoria Navarro-Compán, Francesco Ciccia, Jean Dudler

Förderung

  • Eli Lilly and Company

Zitieren

APA

Rudwaleit, M., Navarro-Compán, V., Russ, H., Panni, T., Filippi, E., Nassab, M. H., Liu-Leage, S., Goëb, V., Ciccia, F., & Dudler, J. (2025). BASDAI and ASDAS disease states in relationship to ASAS40 response: post hoc analysis of ixekizumab in radiographic axial spondyloarthritis. Rheumatology Advances in Practice, 9(2). https://doi.org/10.1093/rap/rkaf012

Vancouver

Rudwaleit M, Navarro-Compán V, Russ H, Panni T, Filippi E, Nassab MH, et al. BASDAI and ASDAS disease states in relationship to ASAS40 response: post hoc analysis of ixekizumab in radiographic axial spondyloarthritis. Rheumatology Advances in Practice. 2025;9(2). doi:10.1093/rap/rkaf012

BibTeX
@article{Rudwaleit2025,
  author = {Rudwaleit, Martin and Navarro-Compán, Victoria and Russ, Hagen and Panni, Tommaso and Filippi, Erica and Nassab, Mani Haschemi and Liu-Leage, Soyi and Goëb, Vincent and Ciccia, Francesco and Dudler, Jean},
  title = {BASDAI and ASDAS disease states in relationship to ASAS40 response: post hoc analysis of ixekizumab in radiographic axial spondyloarthritis},
  journal = {Rheumatology Advances in Practice},
  year = {2025},
  volume = {9},
  number = {2},
  doi = {10.1093/rap/rkaf012}
}
Kostenlos starten →